Juncture Wealth Strategies’s Neurocrine Biosciences NBIX Stock Holding History

Juncture Wealth Strategies’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$887K	Buy	5,262 +719	+16%	+$107K	0.23%	70
2026 Q1	$598K	Sell	4,543 -253	-5%	-$33.6K	0.2%	70
2025 Q4	$680K	Buy	4,796 +125	+3%	+$18.1K	0.22%	62
2025 Q3	$656K	Buy	4,671 +684	+17%	+$92.7K	0.22%	62
2025 Q2	$501K	Sell	3,987 -2,766	-41%	-$317K	0.18%	71
2025 Q1	$747K	Sell	6,753 -529	-7%	-$67K	0.29%	61
2024 Q4	$994K	Sell	7,282 -1,116	-13%	-$138K	0.37%	42
2024 Q3	$968K	Sell	8,398 -200	-2%	-$27.4K	0.37%	42
2024 Q2	$1.18M	Buy	8,598 +173	+2%	+$23.7K	0.5%	35
2024 Q1	$1.16M	Buy	8,425 +343	+4%	+$46.8K	0.5%	37
2023 Q4	$1.06M	Buy	+8,082	New	+$930K	0.48%	38

Other funds holding NBIX

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

PBBUPS

PKO BP Bankowy Universal Pension Society Warsaw, Poland $350M AUM 272.18% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Ellsworth Advisors Hudson, Ohio $609M AUM 52.37% 1-Year Est. Return

PensionDanmark Copenhagen O, Denmark $12B AUM

YCM

Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

Juncture Wealth Strategies's NBIX Position: Q2 2026 in Review

Juncture Wealth Strategies increased its Neurocrine Biosciences (NBIX) stake by 16% in Q2 2026, buying an estimated $107K and bringing the position to 5,262 shares worth $887K. The position accounts for 0.23% of the portfolio, ranked #70.

Juncture Wealth Strategies first reported a position in NBIX in Q4 2023 and has held it in 11 quarters since. The position peaked at $1.18M in Q2 2024. 84 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Juncture Wealth Strategies held 5,262 shares of Neurocrine Biosciences worth $887K as of Q2 2026.
Juncture Wealth Strategies bought 719 Neurocrine Biosciences shares in Q2 2026, an estimated $107K.
Neurocrine Biosciences made up 0.23% of Juncture Wealth Strategies's portfolio in Q2 2026, its #70 holding.
Juncture Wealth Strategies first reported a position in Neurocrine Biosciences in Q4 2023 and has held it in 11 quarters since.
Juncture Wealth Strategies's Neurocrine Biosciences position peaked at $1.18M in Q2 2024.
84 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Juncture Wealth Strategies's 13F filing for Q2 2026, filed 9 Jul 2026.